Beta-Lactamase Inhibition in Antimicrobial Therapy

Beta-lactam antibiotics remain foundational in the fight against bacterial infections. Their mechanism relies on the four-membered β-lactam ring, essential for binding penicillin-binding proteins and inhibiting cell-wall synthesis. However, the emergence of β-lactamases—enzymes secreted by bacteria that hydrolyse and inactivate β-lactams—poses a grave threat to treatment efficacy and global health. To counteract this resistance mechanism, β-lactamase inhibitors have been developed. These compounds, administered in combination with β-lactam antibiotics, act by binding irreversibly to β-lactamase active sites or by evading enzymatic hydrolysis. Among the most widely used are clavulanate, sulbactam and tazobactam, which restore or extend the spectrum of existing β-lactams against resistant strains. Recent strategies have expanded to include novel non-β-lactam inhibitors, structure-guided design of molecules targeting diverse β-lactamase classes and optimisation of pharmacokinetic properties to ensure effective tissue penetration. The integration of inhibitor–antibiotic pairs has transformed clinical practice, enabling effective management of infections caused by extended-spectrum β-lactamase (ESBL) and AmpC-producing Enterobacterales, as well as certain carbapenemase producers. Continued innovation in inhibitor chemistry and combination therapy regimens is crucial to preserve the utility of β-lactam antibiotics and to address the escalating challenge of antimicrobial resistance worldwide.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Beta-Lactamase Inhibition in Antimicrobial Therapy publication trend

The graph below shows the total number of articles in beta-lactamase inhibition in antimicrobial therapy across all publications each year (not limited to Nature Index journals).

Technical terms

β-lactam ring: A four-membered cyclic amide core essential for antibacterial activity of penicillins, cephalosporins and related antibiotics.

β-lactamase: An enzyme produced by bacteria that hydrolyses the β-lactam ring, rendering β-lactam antibiotics inactive.

Extended-spectrum β-lactamase (ESBL): A class of β-lactamases capable of hydrolysing oxyimino-cephalosporins and monobactams, conferring resistance to broad-spectrum β-lactams.

Clavulanate, Sulbactam, Tazobactam: β-lactamase inhibitors containing β-lactam-like structures that bind irreversibly to β-lactamase active sites to protect partner antibiotics.

Structure–activity relationship (SAR): The relationship between the chemical structure of a molecule and its biological activity, guiding rational drug design.

References

1. Piperacillin-tazobactam: prospects for use in real-world practice. Real-World Data & Evidence (2023).
2. Design, synthesis, and evaluation the anti-β-lactamase activity of new sulphathiazole-derived monobactam compounds. Iraqi Journal of Pharmacy (2020).